Lincoln Pharmaceuticals Limited held its Board of Directors meeting on Thursday, August 13, 2026, which commenced at 10:30 AM and concluded at 11:30 AM. The meeting was conducted pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Results Approval

The Board approved the un-audited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2026. The results were reviewed by the audit committee and include a limited review report from the auditors, Samir M. Shah & Associates.

Standalone Financial Results (₹ in Lakhs)

Income:

  • Revenue From Operations: ₹17,728.21
  • Other Income: ₹426.46
  • Total Income: ₹20,154.67

Expenses:

  • Cost of Material Consumed: ₹5,857.86
  • Purchase of Stock-In-Trade: ₹2,093.36
  • Changes In Inventories: ₹563.09
  • Employee Benefits Expenses: ₹3,331.03
  • Finance Costs: ₹25.87
  • Depreciation and Amortisation Expense: ₹388.43
  • Other Expenses: ₹3,139.65
  • Total Expenses: ₹15,399.29

Profitability:

  • Profit Before Exceptional Items & Tax: ₹4,755.38
  • Exceptional Items: Nil
  • Profit After Exceptional Items But Before Tax: ₹4,755.38

Tax Expense:

  • Current Tax: ₹535.30
  • Deferred Tax: ₹596.63
  • Short/(Excess) Tax Provision: Nil

Net Results:

  • Net Profit For The Period: ₹3,623.45
  • Other Comprehensive Income: ₹41.88
  • Total Comprehensive Income: ₹3,665.33

Capital Structure:

  • Paid-Up Equity Share Capital (Face Value ₹10): ₹2,002.97
  • Other Equity: ₹73,760.23

Earnings Per Share (₹10 each, not annualized):

  • Basic: ₹18.09
  • Diluted: ₹18.09

Consolidated Financial Results (₹ in Lakhs)

The consolidated results include Lincoln Pharmaceuticals Limited (Parent Company) and Zullinc Healthcare LLP (Wholly-Owned Subsidiary Company). The financial figures for the consolidated results are identical to the standalone results for the quarter ended June 30, 2026, with no material contributions from subsidiaries.

Auditor's Review

Samir M. Shah & Associates conducted a limited review of both standalone and consolidated financial results and concluded that nothing came to their attention suggesting material misstatement or non-disclosure of required information under Regulation 33 of SEBI Listing Regulations.

Media Release Highlights

Q1 FY27 Financial Performance (Consolidated):

  • Total Income: ₹201.55 crore, up 19.02% YoY
  • EBITDA: ₹51.70 crore, up 32.29% YoY
  • Profit Before Tax: ₹47.55 crore, up 34.36% YoY
  • Net Profit: ₹36.23 crore, up 30.90% YoY
  • EPS: ₹18.09

Full Year FY26 Performance:

  • Total Income: ₹704.48 crore (9.10% YoY growth)
  • EBITDA: ₹131.14 crore (5.78% YoY growth)
  • Net Profit: ₹87.89 crore (6.74% YoY growth)
  • Recommended dividend: 18% (₹1.80 per share on face value ₹10), subject to shareholder approval

Business Highlights and Future Outlook

  • Targeting ₹1,000 crore revenue over next three years with 15-18% annual growth rate
  • Strong performance in cardiac, diabetic, dermatology, and ENT segments
  • Exports to 60+ countries with plans to expand to 90 countries in 2-3 years
  • Recent entry into Canadian market and approvals from TGA Australia and EU GMP
  • Developed 600+ formulations across 15 therapeutic areas
  • 1,700+ registered products with 700 products under development
  • Company remains net-debt free
  • FII holding: 4.60% as of June 30, 2026
  • CRISIL reaffirmed 'CRISIL A/Stable/CRISIL A1' ratings on bank facilities

Manufacturing and Operations

  • State-of-the-art manufacturing facility at Khatraj, Ahmedabad, Gujarat
  • Certifications: EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015, ISO-45001:2018
  • Strong R&D team with 30+ scientists
  • Filed 25+ patent applications, awarded 7 patents
  • Solar plants at Mehsana factory, Khatraj factory, and Radhanpur, plus two windmills
  • Nearly 100% green renewable energy consumption

Management Commentary

Mr. Munjal Patel, Director, stated: "We have started FY27 with a clear focus on building on our existing growth momentum while strengthening the core areas of our business. We are also evaluating opportunities to expand our reach across domestic territories and international markets, supported by our manufacturing capabilities and product pipeline."